FindTrial
Sign In

Expression and clinical significance of PD-1 and TIM3 on acute leukemia / myelodysplastic syndrome

Expression and clinical significance of PD-1 and TIM3 on acute leukemia / myelodysplastic syndrome

Status
Unknown
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072373
Enrollment
Unknown
Registered
2023-06-12
Start date
2023-06-21
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopathy

Interventions

Case group:Standardized medication according to CSCO guidelines
Healthy control group:None

Sponsors

Jiaozuo People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All patients were examined by cytomorphology, immunology, cytogenetics and molecular biology, and all patients met the diagnostic criteria and risk grade of newly diagnosed acute leukemia (AML/ALL) and myelodysplastic syndrome (MDS); 2. Patients have not received radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.; 3. The patient has complete case data (current medical history, past history and auxiliary examination) 4. The patient and his family members signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe underlying diseases; 2. Combined with other malignant tumors; 3. Recently, there are systemic infectious diseases 4. Incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
programmed-1;TIM-3;—

Countries

China

Contacts

Public ContactQinglin Song

Jiaozuo People's Hospital

1026820087@qq.com+86 133 4391 8658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026